Sandra Rojas-Caro, M.D. has been appointed chief medical officer at Aeglea BioTherapeutics, Inc., a biotechnology company developing enzyme-based therapeutics to treat inborn errors of metabolism and cancer.   Dr. Rojas-Caro will oversee the medical strategy and clinical development of Aeglea’s pipeline. She brings more than 15 years of protein therapeutics and small molecule drug development experience.   Previously, she served as group vice president of Clinical Research and Development at...